Sun Pharma Receives Bullish Recommendation from Choice Institutional Equities, Target Price Set at Rs 2300
Sun Pharma's Acquisition of OGN Seen as Transformational Deal
Sun Pharma's recent acquisition of OGN is expected to have a profound impact on the company's financials, with revenue more than doubling to USD 12 billion and an EBITDA margin of approximately 30%. This strategic move is anticipated to enhance the company's portfolio quality by entering the biosimilars market, strengthen its leadership in the women's health segment, and increase the contribution of innovative products to revenue to approximately 26%, up from 20%.
The acquisition marks a significant expansion of Sun Pharma's presence in China, the world's second-largest market, and reduces the company's dependence on the US market to approximately 27%, down from 31%. While the USD 9.5 billion debt raise and USD 4 billion cash outlay may be a concern, Sun Pharma's management is seen as being deliberate in its debt-deployed strategy, rather than risk-averse. This approach underscores the company's willingness to leverage its balance sheet for transformational opportunities.
Supported by Sun Pharma's proven record of strong cash flows, analysts remain confident in the company's ability to gradually deleverage over time. Although interest expenses may remain elevated in the medium term, the strategic benefits of the acquisition are expected to outweigh the near-term drag.
Outlook
Full integration of the OGN acquisition is expected to be completed by FY27E. Based on this, the company's valuation has been revised to 25x FY28E EPS, with a revised target price of INR 2,300, up from INR 1,825. As a result, the rating has been upgraded to BUY.
Comparison of Sun Pharma's Revenue and Dependence on US Market Before and After OGN Acquisition
| Metric | Pre-Acquisition | Post-Acquisition |
|---|---|---|
| Revenue (USD Bn) | N/A | 12 |
| EBITDA Margin | N/A | 30% |
| Dependence on US Market | 31% | 27% |
| Innovative Products' Contribution to Revenue | 20% | 26% |
Investor Takeaway
Investors should consider Sun Pharma's potential for growth and expansion following its acquisition of OGN.
More in Market
Market Analysis: Key Stocks to Watch - Narayana Hrudayalaya, ABB India, Federal Bank, Premier Energies, Ather Energy and More
FirstClub Secures $55 Million in Funding from Peak XV, Sofina, and Other Investors 9 Months After $22 Million Series A Round
Global Markets: Key Indicators to Monitor in Today's Trading Session
